A long-running dispute over licensing of prostate cancer drugs has ended in the University of California’s favor.
California’s Supreme Court last week upheld lower court rulings in favor of the University of California Board of Regents. The decision effectively awards the university $32 million in additional licensing income while also resolving contract claims against the regents and confirming a jury verdict clearing a drug inventor of fraud...
No comments:
Post a Comment